MIM
FBRX

MetLife Investment Management’s Forte Biosciences FBRX Stock Holding History

MetLife Investment Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244K Buy
+11,471
New +$272K ﹤0.01% 2315
2021
Q3 		– Sell
-183
Closed -$154K – 2575
2021
Q2 		$154K Buy
+183
New +$165K ﹤0.01% 2314

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

MetLife Investment Management's FBRX Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Forte Biosciences (FBRX) in Q2 2026: 11,471 shares worth $244K. The stake represents ﹤0.01% of the portfolio and ranks #2315 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in FBRX as recently as Q2 2021.

MetLife Investment Management first reported a position in FBRX in Q2 2021 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • MetLife Investment Management held 11,471 shares of Forte Biosciences worth $244K as of Q2 2026.
  • Forte Biosciences was a new MetLife Investment Management position in Q2 2026.
  • Forte Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2315 holding.
  • MetLife Investment Management first reported a position in Forte Biosciences in Q2 2021 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.